Blog
RSS FeedPosted by Michael Wonder on 12 Nov 2015
Coagulation factor IX FC fusion protein (Alprolix): treatment cost comparison and budget impact analysis
9 November 2015 - CADTH's final science report is now available for the project on coagulation factor IX FC fusion protein ...
Posted by Michael Wonder on 05 Nov 2015
NICE not in favour of drug for neuroblastoma
5 November 2015 - It looks like children and adolescents with neuroblastoma will not be able to access United Therapeutics’ Unituxin ...
Posted by Michael Wonder on 05 Nov 2015
Edoxaban tosylate: considerable additional benefit for certain patients
2 November 2015 - IQWiG finds an indication of a considerable additional benefit in comparison with vitamin K antagonists for the ...
Posted by Michael Wonder on 05 Nov 2015
Breast cancer drug Kadcyla to remain on NHS after manufacturer lowers price
5 November 2015 - The drug was set to be dumped from UK’s list of approved medicines before a deal ...
Posted by Michael Wonder on 04 Nov 2015
CADTH recommends Entyvio for patients with ulcerative colitis
28 October 2015 - CADTH's CDEC has recommended that vedolizumab be listed for the treatment of adult patients with moderately ...
Posted by Michael Wonder on 04 Nov 2015
CADTH calls for feedback on cancer biomarker testing
4 November 2015 - A draft environmental scan document on cancer biomarker testing is available for feedback from all interested stakeholders. ...
Posted by Michael Wonder on 04 Nov 2015
NICE gives green light to dry eye disease treatment in final draft guidance
4 November 2015 - NICE has published final draft guidance recommending ciclosporin (Ikervis) manufactured by Santen Pharmaceutical) for treating severe keratitis ...
Posted by Michael Wonder on 04 Nov 2015
Pharmac hits back at claims Australia has better access to high-cost cancer drugs
3 November 2015 - Pharmac has rebuffed claims New Zealanders have less access to cutting-edge cancer treatments, commissioning research they say ...
Posted by Michael Wonder on 04 Nov 2015
Pharmaceutical Benefits Advisory Committee Guidelines Review
4 November 2015 - The public consultation process on the items included in the PBAC Guidelines Review closed on 14 September ...
Posted by Michael Wonder on 03 Nov 2015
New Chair (elect) of CADTH pCODR Expert Review Committee appointed
2 November 2015 - Dr. Brian O’Rourke, President and CEO of CADTH, today announced that Maureen Trudeau, MD, FRCPC, has been ...
Posted by Michael Wonder on 03 Nov 2015
NZers getting access to best cancer medicines says PHARMAC
3 November 2015 - A new analysis of cancer medicine access in Australia and New Zealand shows that New Zealanders are ...
Posted by Michael Wonder on 02 Nov 2015
Edoxaban tosylate has considerable additional benefits for certain patients says IQWiG
2 November 2015 - Edoxaban tosylate (Lixiana) has considerable additional benefit when compared to vitamin K antagonists for the prevention of ...
Posted by Michael Wonder on 02 Nov 2015
Changes to number of copies of the economic model and category 1 requirements to be filed with CADTH
2 November 2015 - Going forward, CADTH has revised the number of copies of the economic model to be provided at ...
Posted by Michael Wonder on 02 Nov 2015
Over-the-counter items recommended for de-listing or amendment from 1 January 2016
2 November 2015 - A number of over-the-counter products will delisted from the PBS on 1 January 2016 if the Minister ...
Posted by Michael Wonder on 02 Nov 2015
Public Summary Documents - July 2015 PBAC meeting
2 November 2015 - The Public Summary Documents from the July 2015 PBAC meeting are now available. ...